Lack Of Competition Equals Higher Drug Prices: HHS Analysis Is Slogan In Search Of Solutions

Findings could provide a basis for future policy interventions, the department says. Speeding generics and biosimilars would seem a natural outshoot of the conclusions, but the report does not contain any recommendations.

Report Spotlights Lack Of Competition In Biologics Sector • Source: Shutterstock

More from Pricing Debate

More from Market Access